NCT02347852 - Assessment of Physical Activity During Therapy With Regorafenib for Metastatic Colorectal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 20, 2015

Primary Completion Date

September 8, 2016

Study Completion Date

September 8, 2016

Conditions

Colorectal Neoplasms

Interventions

DRUG

Regorafenib (Stivarga, BAY73-4506)

Stivarga is available as tablets (40 mg). It is taken in four-week treatment cycles at a recommended starting dose of 160 mg once every day for three weeks, followed by a week off.

Trial Locations (1)

4600

Klinikum Kreuzschwestern Wels GmbH, Multiple Locations